A Study to Evaluate Effect of Verapamil and Food of Sevasemten in Healthy Volunteers
← catalyst calendarSponsored by Edgewise Therapeutics, Inc. (industry) · EWTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
42actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-08 | actual | When the study began enrolling |
| Primary completion | 2025-02-22 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-22 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Subjects
Interventions
- Drug: sevasemten
- Drug: Verapamil
Primary outcomes
what the primary-completion date above is the date OFPharmacokinetic
measured Up to 46 days of monitoring
Pharmacokinetic
measured Up to 46 days of monitoring
Pharmacokinetic
measured up to 42 days of monitoring
Pharmacokinetic
measured up to 42 days of monitoring
Pharmacokinetic
measured up to 42 days of monitoring
Pharmacokinetic
measured up to 42 days of monitoring
Permalink · EWTX's whole pipeline · Catalyst calendar · Every registered study · What changed